Page 11 - Cipla

Nifty Pharma outshines benchmarks, up 2%; Cipla, Sun Pharma hit 52-wk highs

Shares of Glenmark Pharma, Granules India, Divi's Laboratories, Torrent Pharma, Lupin and Aurobindo Pharma, surged in the range of 2 per cent to 6 per cent in Monday's intra-day trade

Indian generic formulation-makers level of capex declining: Candle Partners

Candle Partners study shows that from the peak of 30% of gross block in FY16, the capex is down to 9-10% of gross block

Growth forecast in US market set to drive gains for Cipla stock

Street remains bullish on India prospects, regulatory headwinds for Goa site continue

Nifty Pharma index sees biggest jump in four months, shows data

The Nifty Pharma index finished at 12,750, up 3.1 per cent - most since May 20 and third biggest single-day gain of the year

NLEM 2022: Analysts see no major impact pharma companies' growth

The 2022 revision of the NLEM came after seven years. Most drugs that have been now brought into the NLEM include anti-infectives, anti-diabetics, anesthetics, etc

Fight against Covid-19: Here is a list of vaccines approved in India

Besides Bharat Biotech's nasal vaccine, India has 13 vaccines to fight against Covid-19. Two have been approved for manufacturing, while 11 have been approved for emergency use

Sensex slides 861 pts, Nifty holds 17,300; RIL slips 1% post 45th AGM

CLOSING BELL: Mukesh Ambani laid out succession plan with Akash Ambani championing telecom, Isha Ambani controlling Retail, and Anant Ambani joining new-energy vertical

The pink of health: Trade generics now key growth driver for Cipla

Vertical witnesses 25% CAGR in 5 yrs

Stocks to Watch: Cipla, NTPC, Adani group, SBI Cards, Hind Zinc, Nxtdigital

Stocks to Watch: ICICI Securities, Axis Capital and Citigroup Global Markets are among the 5 investment bankers selected to manage the sale of the government's 29.53% residual stake in Hindustan Zinc

India at 75: These pre-independence companies thrived in independent India

These companies that operated under the constraints of British rule before 1947 helped India become self-sufficient in various sectors after independence

Cipla betting big on digitisation and emerging segments like mRNA

Drug major Cipla is betting big on digitisation and emerging segments like biosimilars and mRNA aided medications to drive its next phase of growth. The Mumbai-based drug maker is also bullish on maximising value opportunity in the complex generics in the US market. It is also looking to scale up its US core formulations sales on the back of respiratory and peptide franchises while monitoring upcoming complex product launches in the second half of the current fiscal. "Digitalisation in healthcare found its rightful place during the pandemic, and there is a need to expand and support the essential backup services to enable digital healthcare to function efficiently in all primary and secondary healthcare centres," Cipla Executive Vice-Chairperson Samina Hamied said in the company's Annual Report for 2021-22. The drug firm has embarked on the digital transformation of the value chain across functions, including finance, R&D, manufacturing, supply chain, HR, customer outreach and ...

Stocks to Watch: YES Bank, Cipla, Bank of Baroda, Zomato, HDFC, ITC, NTPC

Stocks to Watch today: ITC, UPL, Zomato, Arvind, Bajaj Consumer Care, among others will release their Q1 earnings today.

Cipla Q1 net dips 4% to Rs 686 cr, revenue down 2% on tapering Covid sales

Domestic revenue dips 8.4% as Covid-19 share of branded prescription business normalises; North American business up 10% to $155 million

Sensex rises 712 pts, Nifty tops 17,150; Tata Steel rallies 7%, HDFC 2%

CLOSING BELL: Public sector banks were the only losers with the Nifty PSB index down 1.2 per cent

Cipla Q1 net profit dips marginally to Rs 706 cr; revenue falls 2%

The Mumbai-based company had reported a net profit of Rs 710 crore in the April-June quarter of the last fisca

Stocks to watch: HDFC, Sun Pharma, Dr Reddy's, STFC, TVS Motor, SpiceJet

Stocks to watch today: HDFC, Sun Pharma, and Cipla will report their June quarter results on Friday, July 29; Dr Reddy's saw 108 per cent YoY rise in consolidated net profit to Rs 1,187.6 crore in Q1.

Cipla Q1 revenue may be muted on high base, low Covid drug sales: Analysts

Cipla Q1 results preview: Analysts attribute the likely dull performance due to the high base of last year, and the reduction in revenue contribution from Covid-19 therapies in the recent quarter.

Stocks to watch: ACC, L&T Tech, L&T Infotech, JSPL, Glenmark, Tata Elxsi

Stocks to watch today: L&T Technology Services and Jindal Steel and Power will share June quarter 2022 (Q1FY23) results on Friday, July 15.

Stocks to Watch Today: Cipla, RIL, PNB, Reliance Power, Metals, Restaurants

Stocks to Watch Today: Shares of metal companies are also to be in focus as copper prices fell to 17-month lows amid new COVID restrictions in China, slowing global manufacturing activity and a jump i

Sensex, Nifty end flat after volatile session; metal, energy stocks shine

CLOSING BELL: M&M, Tech M, Dr Reddy's Labs, Reliance Industries, HCL Tech, and Tata Steel were the top gainers on the 30-pack index